Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × mCRPC × 1 year × Clear all

Phase

Status

Not yet recruiting 2 Recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 595 Carcinoma, Non-Small-Cell Lung 409 Prostatic Neoplasms 346 Neoplasms 344 Lung Neoplasms 222 Multiple Myeloma 218 Colorectal Neoplasms 201 Neoplasm Metastasis 186 Melanoma 180 Leukemia, Myeloid, Acute 156 Ovarian Neoplasms 148 Pancreatic Neoplasms 138 Squamous Cell Carcinoma of Head and Neck 126 Brain Neoplasms 126 Lymphoma 123 Glioblastoma 122 Carcinoma, Renal Cell 119 Recurrence 115 Leukemia, Lymphocytic, Chronic, B-Cell 113 Lymphoma, Non-Hodgkin 112 Carcinoma, Hepatocellular 107 Precursor Cell Lymphoblastic Leukemia-Lymphoma 100 Triple Negative Breast Neoplasms 98 Head and Neck Neoplasms 97 Urinary Bladder Neoplasms 90 Lymphoma, Large B-Cell, Diffuse 88 Hematologic Neoplasms 88 Stomach Neoplasms 86 Sarcoma 84 Lymphoma, Follicular 82

Interventions

talazoparib 1 enzalutamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03395197 2026-03-12

TALAPRO-2

Pfizer

Phase 3 Active not recruiting

1,054 enrolled 21 charts 1 FDA

mCRPC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡